Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Polaryx Therapeutics, Inc. - Common Stock (NQ:PLYX)

2.034 -0.055 (-2.66%)
Streaming Delayed Price Updated: 10:09 AM EDT, Sep 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Polaryx Therapeutics, Inc. - Common Stock

News headline image
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards
Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award Winner 
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
Company selected as a Diamond honoree for Excellence in Pediatric Care 
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™
Oral presentation highlighted the effect of gemfibrozil on Krabbe disease, one of four LSDs in the upcoming Phase 2 SOTERIA basket trial evaluating PLX-200 (reformulated gemfibrozil) 
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx Therapeutics Welcomes New Members of the Board of Directors
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
News headline image
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial designed to evaluate the safety and clinical activity of lead drug... 
From Polaryx Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.